Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

893 recalls · Class II, newest first

Class II · Moderate risk

A1 Slim

Marketed Without An Approved NDA/ANDA: FDA analysis found this product to contain undeclared sibutramine, phenolphthalein, and n-desmethyl sibutramine, making this an unapproved drug for which safety and efficacy have not been established and therefore, subject to recall.

Terminated Chemical / undeclared Kiriko, LLC. D-0058-2018
Class II · Moderate risk

Bisoprolol Fumarate tablets

Failed Impurities/Degradation Specifications: Out of Specification for an unknown impurity was observed during the 18 month stability testing.

Terminated Impurity / degradation Unichem Pharmaceuticals Usa Inc NDC 29300-126-13 D-0010-2018
Class II · Moderate risk

Lorazepam Tablets

Labeling: Label Error on Declared Strength. Bottle labeled as 0.5 mg tablets contained 1mg tablets of lorazepam

Terminated Labeling / mix-up Leading Pharma, LLC NDC 69315-904-05 D-0085-2018
Class II · Moderate risk

Glutamine

CGMP Deviations; FDA analysis deterrmined that the product does not contain glutamine and two unknown impurities were observed

Terminated Impurity / degradation United Pharmacy D-0008-2018
Class II · Moderate risk

Alprazolam Tablets

Failed Impurities/Degradation Specifications: Out-of-specification result for an unknown impurity.

Terminated Impurity / degradation The Harvard Drug Group NDC 0904-5858-61 D-0013-2018
Class II · Moderate risk

methylPREDNIsolone ACETATE

Lack of Assurance of Sterility; autoclave parameters were not correct for one of two autoclaves used to sterilize the product.

Terminated Sterility / contamination RXQ Compounding LLC D-0012-2018

Recalls by year